FGF21 and Cirrhosis: Additionally, Akero therapeutics reported that efruxifermin (EFX), an FGF21-targeting drug, demonstrated a 39% reversal of cirrhosis in a Phase 3 study compared to only 15% in the placebo group [30], further emphasizing the potential of novel therapeutic interventions.